The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLL

Amy Johnson, PhD
Published Online: 5:47 PM, Fri December 11, 2015


Amy Johnson, PhD, associate professor, Hematology, Ohio State University, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196). Acalabrutinib is a selective, irreversible BTK inhibitor designed to improve both the safety and efficacy of BTK inhibitors in CLL.


Johnson says there is currently neither a subtype of patient with CLL that benefits from acalabrutinib, nor is there a subtype that suffers from the treatment. 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.